ARC (Association of Related Churches) Announces 2023 ARC 7-02-2023, 22:44

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda 6-10-2024, 05:24